Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;8(3):318-24.
doi: 10.1093/ckj/sfv030. Epub 2015 May 7.

The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease

Stefaan J Vandecasteele  1 , Sara Ombelet  1 , Sophie Blumental  2 , Willy E Peetermans  3
Affiliations

The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease

Stefaan J Vandecasteele et al. Clin Kidney J. 2015 Jun.

Abstract

Background: In the general population, pneumococcal polysaccharide vaccines (PPV) decrease the incidence of invasive pneumococcal disease (IPD) whereas the impact on the prevention of noninvasive pneumococcal disease is less clear. As compared with PPV, pneumococcal conjugate vaccines (PCV) provoke a higher, longer-lasting immune response resulting in a 45% decreased incidence in vaccine-type pneumonia, and a 75% decrease in vaccine-type IPD.

Methods: Literature review on pneumococcal vaccination in end-stage renal disease.

Results: As compared with the general population, patients with chronic kidney disease (CKD) suffer increased mortality and morbidity from pneumococcal disease (PD), being up to 10-fold for those treated with dialysis. Numerous, usually small and methodological heterogeneous studies demonstrate that PPV provokes a serological response in dialysis patients, kidney transplant recipients, children with nephrotic syndrome and CKD patients receiving immunosuppressive medication. This response is of less intensity and duration than in healthy controls. Similar observations were made for the PCV. The protective value of these vaccine-elicited anti-pneumococcal antibodies in the CKD population remains to be substantiated. For patients treated with dialysis, epidemiological data demonstrate a correlation-which does not equal causality-between pneumococcal vaccination status and a slightly decreased total mortality. Clinical outcome data on the effectiveness of pneumococcal vaccination in the prevention of morbidity and mortality in the CKD population are lacking.

Conclusions: Awaiting better evidence, pneumococcal vaccination should be advocated in all patients with CKD, as early in their disease course as possible. The ACIP schedule recommends a PCV-13 prime vaccination followed by a PPV-23 repeated vaccine at least 8 weeks later in pneumococcal non-vaccinated patients, and a PCV-13 vaccine at least 1 year after the latest PPV vaccine in previously vaccinated patients. In the UK, vaccination with PPV-23 only is recommended. There exist no good data supporting re-vaccination after 5 years in the dialysis population.

Keywords: antibody; dialysis; pneumococcal vaccination; prevention; transplantation.

PubMed Disclaimer

References

    1. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 2014; 20 (Suppl 5): 45–51 - PubMed
    1. Aliberti S, Mantero M, Mirsaeidi M, et al. The role of vaccination in preventing pneumococcal disease in adults. Clin Microbiol Infect 2014; 20 (Suppl 5): 52–58 - PMC - PubMed
    1. Bogaert D, De GR, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144–154 - PubMed
    1. Robinson J. Efficacy of pneumococcal immunization in patients with renal disease—what is the data? Am J Nephrol 2004; 24: 402–409 - PubMed
    1. Klapdor B, Ewig S, Pletz MW, et al. Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J 2012; 39: 1156–1161 - PubMed